BNNT/PatentMatch huggingface dataset:
Please select the most similar patent number from A, B, C and D. Which number is?
Disclosed are an edible blending oil with the function of preventing atherosclerosis and a preparation method therefor, containing a weight ratio of 0.2-0.4 : 0.9-1.1: 0.8-1.2 of saturated fatty acids (SFA), monounsaturated fatty acids (MUFA) and polyunsaturated fatty acids (PUFA), wherein the weight ratio of ω-6 polyunsaturated fatty acids (ω-6 PUFA) to ω-3 polyunsaturated fatty acids (ω-3 PUFA) is 2-8.5 : 1; and taking the selected raw materials and putting them into the dosing tank under stirring at a slow speed for 30-40 min at the ambient temperature of 20-40°C according to the above-mentioned dosage ratio, and the edible oil will then be obtained.
A: A structured emulsion, comprising: 2-6% of an oil phase composition, 7-20% of a water-soluble composition, and 74-92% of water. In terms of fatty acids in the oil phase composition, the content of saturated fatty acids is less than or equal to 45%, the content of monounsaturated fatty acids is less than or equal to 50%, and the content of polyunsaturated fatty acids is less than or equal to 30%. The oil phase composition contains 0.4-2.9% of phospholipids on the basis of the total lipid mass.
B: Disclosed are an edible antioxidant oil gel and a preparation method therefor, wherein the edible antioxidant oil gel mainly consists of the following raw materials in parts by weight: 40-60 parts of an edible vegetable oil, 5-15 parts of policosanol, 2-8 parts of a protein and 30-50 parts of water. The edible antioxidant oil gel can be used in solid or semi-solid foods instead of trans-fatty acids and saturated fatty acids.
C: A vitamin K2 microcapsule, a preparation method therefor, and an application thereof in preparation of a medicine for preventing and treating cardiovascular and cerebrovascular diseases. The vitamin K2 microcapsule contains the following components in parts by weight: 0.001-10 parts of vitamin K2, 5-30 parts of a polyunsaturated fatty acid source, 0.1-10 parts of vitamin E polyethylene glycol succinate, 50-95 parts of a water-phase wall material, and 0.01-10 parts of an antioxidant, the polyunsaturated fatty acid source containing an ω-6 source and an ω-3 source, and the antioxidant being a water-phase antioxidant and/or an oil-phase antioxidant. The vitamin K2 microcapsule prepared by the method has good water solubility and stability and high bioavailability, can significantly improve preventive and/or therapeutic effects on cardiovascular and cerebrovascular diseases, and has broad application prospects.
D: A pig feed capable of increasing the content of unsaturated fatty acid in pork fat. The pig feed contains microalgae with eicosapentaenoic acid, wherein the content by weight of the eicosapentaenoic acid is 0.005%-0.12%. The pig feed can effectively increase the content of unsaturated fatty acid in pork fat of pigs bred with the pig feed, especially, the content of eicosapentaenoic acid and docosahexaenoic acid in ω-3 unsaturated fatty acid.
Answer: B
Please select the most similar patent number from A, B, C and D. Which number is?
The present invention relates to a use of an extract of the overground part of Scutellariae radix in aquaculture. The overground part of Scutellariae radix comprises at least one of Scutellariae radix stems, Scutellariae radix leaves and Scutellariae radix flowers. The extract of the overground part of Scutellariae radix has a good inhibitory effect on aquatic pathogenic microorganisms, does not readily develop drug resistance, and is suitable for large-scale application in aquaculture.
A: A whitening and anti-wrinkle traditional Chinese medicine composition, a mixed extract thereof and an application thereof, the composition comprising Gastrodia elata, Bletilla striata, Cortex moutan, Panax ginseng, Safflower, Panax notoginseng, Salvia miltiorrhiza, Glycyrrhiza uralensis, Lycium chinensis and Scutellaria baicalensis. The mixed extract of the composition can inhibit tyrosine kinase, having an antioxidant effect, promoting the growth of collagen, and being used in cosmetics.
B: An application of baicalein in preparing a drug for preventing and/or treating a disease caused by a novel coronavirus infection. In particular, the present invention relates to the application of baicalein and a baicalein-containing pharmaceutical composition in preparing a drug for preventing and/or treating a disease that is caused by a novel coronavirus (SARS-CoV-2) infection, the infectious disease comprising mild, moderate, and severe infections caused by the novel coronavirus, particularly novel coronavirus pneumonia.
C: Provided are applications of a myristic acid derivative in preparing an animal growth promoter. The myristic acid derivative comprises a salt of myristic acid and a glyceryl ester of myristic acid. The myristic acid derivative has significant inhibitory activities with respect to common infectious bacteria of animals, provides great effects in terms of controlling the rate of diarrhea in animals and improving production performance in animal farming, and is applicable in farmed animals such as livestock, poultry, and aquatic products.
D: A traditional Chinese medicine composition and an application thereof. The traditional Chinese medicine composition is prepared from active pharmaceutical ingredients ephedra, gypsum, weeping forsythia capsule, root of baikal skullcap, white mulberry root-bark, bitter apricot seed, root of grand hogfennel, tuber of pinellia, dried tangerine peel, bulb of fritillary, achene of great burdock, honeysuckle flower, root and rhizome of sorrel rhubarb, platycodon root, and root of ural licorice, and has the effects of resisting virus, protecting organ, and improving immunity.
Answer: C
Please select the most similar patent number from A, B, C and D. Which number is?
Disclosed is method for preparing a deoxycholic acid or ester thereof or pharmaceutically acceptable salt thereof. The compound is suitable for removing fat deposition.
A: The present invention relates to the technical field of medicine, and relates in particular to a hexanone glycokinase inhibitor compound, a pharmaceutically acceptable salt thereof, an ester thereof or a stereoisomer thereof, a pharmaceutical composition and preparation comprising the compound, the pharmaceutically acceptable salt thereof, the ester thereof or the stereoisomer thereof, a method for preparing the compound, the pharmaceutically acceptable salt thereof, the ester thereof or the stereoisomer thereof, and a use of the compound, the pharmaceutically acceptable salt thereof, the ester thereof or the stereoisomer thereof in the preparation of a drug for the treatment and/or prevention of diseases mediated by KHK and related diseases. (I)
B: The present invention relates to a method for preparing a chenodeoxycholic acid derivative. Particularly, disclosed is a method for carrying out one-pot reduction on a compound represented by formula (Ⅵ), i.e., 3α-hydroxyl-ethidene-7-ketone-5β-chole-24-alkamide, to obtain a compound represented by formula (Ⅴ), i.e., 3α,7α-dyhydroxyl-6α-ethyl-5β-cholanic acid, and then carrying out salt formation crystallization to obtain a high-purity obeticholic acid sodium salt, a potassium salt, a magnesium salt, and a calcium salt.
C: The present invention relates to the technical field of medicine, in particular to a tricyclic USP1 inhibitor compound, a pharmaceutically acceptable salt thereof, an ester, a deuterated substance or a stereoisomer thereof, a pharmaceutical composition and a preparation containing the compound, the pharmaceutically acceptable salt, the ester, the deuterated substance or the stereoisomer, and a method for preparing the compound, the pharmaceutically acceptable salt, the ester, the deuterated substance or the stereoisomer, and use of the compound, the pharmaceutically acceptable salt, the ester, the deuterated substance or the stereoisomer in the preparation of a medicine for treatment and/or prevention of diseases mediated by USP1 and related diseases.
D: The present invention relates to the technical field of medicine, and particularly relates to a tricyclic ubiquitin specific protease 1 inhibitor compound; a pharmaceutically acceptable salt thereof, an ester thereof, a deuterated compound or a stereoisomer thereof; a pharmaceutical composition and a preparation containing the compound, the pharmaceutically acceptable salt thereof, the ester thereof, the deuterated compound or the stereoisomer thereof; a method for preparing the compound, the pharmaceutically acceptable salt thereof, the ester thereof, the deuterated compound or the stereoisomer thereof; and use of the compound, the pharmaceutically acceptable salt thereof, the ester thereof, the deuterated compound or the stereoisomer thereof in the preparation of a drug for treating and/or preventing diseases mediated by USP1 and diseases related thereto.
Answer: B